The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2026 | ATOMIC: does immunotherapy need chemotherapy to be beneficial in MSI-H/dMMR colon cancer?
Dirk Arnold, MD, PhD, Asklepios Tumorzentrum Hamburg, Hamburg, Germany, discusses insights from the ATOMIC trial (NCT02912559), evaluating the benefit of atezolizumab with mFOLFOX6 chemotherapy versus mFOLFOX6 alone in patients with microsatellite instability-high/deficient mismatch repair (MSI-H/dMMR) colon cancer. Disease-free survival was improved by 50% in the combination arm, making atezolizumab with mFOLFOX6 a global standard of care regimen. Further exploratory retrospective analysis investigated the relative contribution of immunotherapy and chemotherapy by comparing outcomes in patients who received the full course of mFOLFOX6 with those who stopped mFOLFOX6 early. Patients who received the full course of mFOLFOX6 showed a greater benefit from the addition of atezolizumab. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2026 Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
